Company profile
Mesa Laboratories, Inc.
NASDAQ: MLAB · Healthcare · Medical - Equipment & Services
#273 of 1,418 Healthcare companies by revenue46th-percentile growth
EA Score
78B+FH 78DQ 85GM 58SS 86
v0.1 · 65/100 weight · provisional
↑ listing tenure, Piotroski F · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$249.1M
Rev growth YoY (TTM)
+3.4%
Net income (FY)
$6.7M
Employees
717
as of 2026-08-11
Market cap
$568.7M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$249.1M$249.1M2026
Net income$6.7M$6.7M2026
Operating income$18.5M$18.5M2026
Total assets$427.7M$427.7M2026
Liabilities$241.5M$241.5M2026
Equity$186.2M$186.2M2026
Revenue trend
FY2021 – FY2026 · USD
FY21
FY21
FY21
FY22
FY23
FY24
FY25
FY26
Revenue by segment
Filed disclosures · FY2026
By product
Sterilization and Disinfection Control41%
Calibration Solutions21%
Biopharmaceutical Development20%
Clinical Genomics18%
By geography
UNITED STATES47%
Other45%
CHINA8%
The read
What is Mesa Laboratories, Inc.’s revenue?
Mesa Laboratories, Inc. booked $249.1M in FY2026 revenue, growing 3.4% year over year — about the middle of the pack among Healthcare companies we track, at a 2.7% net margin.
Peers · Healthcare
Frontage Holdings Corporation72BLeMaitre Vascular, Inc.80B+American Well Corporation60CKeros Therapeutics, Inc.71BDefinitive Healthcare Corp.53DSTAAR Surgical Company67BNeighbors
Jefferson →Key facts
CEOSiddhartha C. Kadia
SectorHealthcare
IndustryMedical - Equipment & Services
HeadquartersLakewood, CO
ExchangeNASDAQ: MLAB
Employees717
IPO date1984-02-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.